machine-learning-diagnostics
(3)
Inflammatix, Inc.
Inflammatix is a Sunnyvale, California molecular diagnostics company that reads the body's own immune response instead of hunting for the pathogen. Its FDA-cleared TriVerity test measures 29 host mRNAs from a blood sample and, using machine-learning algorithms, returns three scores in about 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and overall illness severity. Run on the company's benchtop Myrna instrument, it is built for emergency and critical-care clinicians who need to decide fast whether a patient is heading toward sepsis. Spun out of Stanford in 2016, the company has raised more than $205M.
Superfluid Dx, Inc.
Superfluid Dx is a South San Francisco diagnostics company building a blood-based test for Alzheimer's disease and other neurodegenerative conditions. Its platform isolates cell-free messenger RNA (cf-mRNA) from a single tube of blood and pairs next-generation sequencing with RNA deconvolution and machine-learning analysis to read out organ-level biology - aiming to detect disease years earlier than conventional methods and to guide therapy. The company was formed in late 2023 when WRQ Sciences acquired and renamed Molecular Stethoscope, and is led by Fluidigm co-founder Gajus Worthington alongside Stanford bioengineer and serial founder Steve Quake.
Tim Sweeney
Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.